Compare AbCellera Biologics Inc (ABCL) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? AbCellera Biologics Inc trades at $7.29 (market cap $2.35B), while YieldMax NVDA Option Income Strategy ETF trades at $12.52. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | NVDY | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $8.12 | $17.96 |
52-Week Low | $2.78 | $12.03 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
NVDY trades at $12.19, up 0.58% on the day, with a bearish technical signal from moving averages but neutral oscillators. The fund generates weekly dividends from its covered call strategy on NVIDIA, with recent payouts ranging from $0.10 to $0.21 per share. News highlights debate whether the income strategy justifies sacrificing NVIDIA's upside potential.
Outlook hinges on NVIDIA's volatility sustaining option premiums; risks include capped gains during NVIDIA rallies. The 1.09% fee and opportunity cost versus direct NVIDIA ownership are key considerations for income-focused investors amid bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
